Responsiveness of choroidal neovascular membranes in patients with R345W mutation in fibulin 3 (Doyne honeycomb retinal dystrophy) to anti-vascular endothelial growth factor therapy

Arch Ophthalmol. 2011 Dec;129(12):1626-8. doi: 10.1001/archophthalmol.2011.338.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bevacizumab
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / genetics
  • Corneal Dystrophies, Hereditary / drug therapy*
  • Corneal Dystrophies, Hereditary / genetics
  • Extracellular Matrix Proteins / genetics*
  • Female
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Male
  • Middle Aged
  • Optic Disk Drusen / congenital
  • Point Mutation*
  • Retrospective Studies
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / physiology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • EFEMP1 protein, human
  • Extracellular Matrix Proteins
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab

Supplementary concepts

  • Doyne honeycomb retinal dystrophy